Search PubMed⌕ Search

Biomedical subjects

S Fukuda

Publications and source records attributed to S Fukuda.

903 records · Page 51Linked to original sources
PubMedDate not supplied

Brain anomalies found in 18 trisomy: CT scanning, morphologic and morphometric study.

Brain anomalies in 9 cases of cytogenetically proven 18 trisomy were reported. In addition to the various cerebral anomalies such as gyral or lobar abnormalities, hippocampal dysplasia, abnormal lateral geniculate body, agenesis or hypoplasia of the corpus callosum, absent or hypoplastic olfactory nerves, small optic tracts, and dysplasia of the inferior olivary nucleus, hypoplasia of the cerebellum and ventral pons was found in all cases. Cranial computed tomography was performed and revealed cerebellar and pontine hypoplasia with or without hypoplasia of the posterior cranial fossa as a characteristic finding in all 9 cases. A comparative morphometric study was done using age-matched controls. Macroscopically, the weight ratio of the cerebellum and brain stem to the whole brain was reduced compared with the controls. Microscopically, the thickness of the internal granular layer of the cerebellum was reduced especially at the convex area.

Brain↗
PubMedDate not supplied

A newly developed hexamethylmelamine derivative, SAE9 with both antitumor and aromatase-inhibitory activity.

Hexamethylmelamine (HMM) has previously been shown to be active against ovarian, breast and small cell lung cancer. However HMM dose not have aromatase-inhibitory activity. A newly developed HMM derivative, 2-N,N-dimethylamino-4, 6-bis (1-H-imidazol-1-yl)-1,3,5-triazine (SAE9), was found to have direct antitumor activity as well as aromatase-inhibitory activity. The direct antitumor activity on breast carcinoma cell lines (MCF-7, R-27 and MDA-MB-231) was assessed using the 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyl tetrazolium bromide (MTT) on cells growing in monolayer culture. The 50% inhibitory concentrations (IC50) of SAE9 were found to be approximately 10(-4) M for each cell line, roughly equivalent to those of HMM. When the aromatase-inhibitory effect was assessed using a human placental aromatase-inhibitory assay, the IC50 of SAE9 was 5.5 x 10(-7) M, which was superior to that of aminoglutethimide (AG) (3.8 x 10(-5) M). In a rat uterine growth model treated with androstenedione as the in vivo aromatase inhibition assay, SAE9 had an effect equivalent to that of AG. Since SAE9 has both antitumor and aromatase-inhibitory activity on breast carcinoma cell lines with estrogen dependency, this and similar non-steroidal aromatase inhibitors are thought to be promising for further study.

Altretamine↗